The stock of Genocea Biosciences Inc (NASDAQ:GNCA) is a huge mover today! About 839,367 shares traded hands or 116.60% up from the average. Genocea Biosciences Inc (NASDAQ:GNCA) has risen 35.66% since February 26, 2016 and is uptrending. It has outperformed by 25.23% the S&P500.
The move comes after 7 months positive chart setup for the $128.52 million company. It was reported on Oct, 1 by Barchart.com. We have $12.09 PT which if reached, will make NASDAQ:GNCA worth $176.07 million more.
Analysts await Genocea Biosciences Inc (NASDAQ:GNCA) to report earnings on November, 3. They expect $-0.42 earnings per share, down 13.51% or $0.05 from last year’s $-0.37 per share. After $-0.39 actual earnings per share reported by Genocea Biosciences Inc for the previous quarter, Wall Street now forecasts 7.69% negative EPS growth.
Genocea Biosciences Inc (NASDAQ:GNCA) Ratings Coverage
Out of 4 analysts covering Genocea Biosciences (NASDAQ:GNCA), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Genocea Biosciences has been the topic of 7 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The rating was maintained by Needham on Tuesday, August 11 with “Buy”. The rating was initiated by UBS with “Buy” on Thursday, December 17. The stock has “Overweight” rating given by PiperJaffray on Thursday, September 29. Piper Jaffray maintained Genocea Biosciences Inc (NASDAQ:GNCA) on Thursday, August 6 with “Overweight” rating. The company was maintained on Thursday, September 29 by Needham. The stock of Genocea Biosciences Inc (NASDAQ:GNCA) has “Buy” rating given on Tuesday, October 20 by Needham. The stock has “Outperform” rating given by FBR Capital on Monday, October 19.
According to Zacks Investment Research, “Genocea Biosciences, Inc. is involved in developing vaccines. The company’s proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts.”
More important recent Genocea Biosciences Inc (NASDAQ:GNCA) news were published by: 247Wallst.com which released: “Genocea Biosciences Posts Positive Herpes Trial Results” on September 29, 2016, also Fool.com published article titled: “Why It’s Been a Wild Few Days for Genocea Biosciences Inc.”, Marketwatch.com published: “Virtual Stock Exchange” on February 05, 2014. More interesting news about Genocea Biosciences Inc (NASDAQ:GNCA) was released by: Fool.com and their article: “Why Genocea Biosciences Inc Stock Dropped Today” with publication date: July 30, 2015.
GNCA Company Profile
Genocea Biosciences, Inc., incorporated on August 16, 2006, is a biopharmaceutical company. The Firm discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses, in contrast to approved vaccines and immunotherapies, which are designed to act primarily through B cell (or antibody) immune responses. The Company’s ATLAS discovery platform is designed to overcome the challenges associated with developing vaccines that stimulate T cell immunity. The Company’s ATLAS is a throughput system for T cell vaccine and immunotherapy discovery. The Firm operates through business of developing and commercializing vaccines segment. The Firm has one product candidate in Phase II clinical development: GEN-003.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.